Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.66 |
| ▸ | TACR1 | P25103 | 9/20 | 0.60 |
| ▸ | DPP4 | P27487 | 4/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115349 | 0.90 | KCNA5 (0.76) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL1382996 | 0.85 | KCNA5 (0.76) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL3122893 | 0.85 | KCNA5 (0.69) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL1379447 | 0.84 | KCNA5 (0.67) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL1378536 | 0.84 | KCNA5 (0.67) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL1381745 | 0.84 | KCNA5 (0.70) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| Hydrochloric Acid SCHEMBL15225930 | 0.83 | KCNA5 (0.66) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL4685936 | 0.82 | KCNA5 (0.65) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL1382177 | 0.81 | KCNA5 (0.64) | KCNA5KCNH2TACR1DPP4MAPK8 | |
| SCHEMBL1379988 | 0.81 | KCNA5 (0.64) | KCNA5KCNH2TACR1DPP4MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667978-B1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | claimed |
| JP-4719151-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| US-7709476-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-05-04 | — | — | US | claimed |
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-18 | — | — | US | claimed |
| EP-1667978-A4 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-08-29 | — | — | EP | claimed |
| EP-1667978-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005046578-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | claimed |
| EP-1667978-B1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-1667978-B1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| US-7709476-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709476-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709476-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-18 | — | — | US | disclosed |
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-18 | — | — | US | disclosed |
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-18 | — | — | US | disclosed |
| EP-1667978-A4 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1667978-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005046578-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046578-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | KCNJ2, KCNQ1, KCNQ2 | KCNA5 23/4885KCNH2 4/4885TACR1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.